FORM 4

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * COOPER ROBIN D G					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) 1180 VETERANS BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 05/21/2004									X Officer (give title below) Other (specify below) Sr. V.P. Pharmaceutical Scs.					
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City	(City) (State) (Zip)		Table I - Non-Derivative Securities Acqui								ired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)		Date (Month/Day/Year)		ZA. Deemed Execution Date, if any (Month/Day/Year)		ĺ	Code (Instr		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			of (D)				6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership		
							Code V		Amount	(A) or (D)	Price	(msu. 3	su. 3 anu 4)		or Indirect (I) (Instr. 4)				
Common	Stock		05/21	1/2004				P	,		700	A	\$ 16.58	700			D		
Common Stock			05/21	1/2004				P	•		100 A \$ 16.59		800			D			
Common Stock		05/21	21/2004				P	•		100	A	\$ 16.65	900			D			
Common Stock		05/21	21/2003			P				100	A	\$ 16.66	1,000	,000		D			
Common	Stock		05/21	1/2004				P	•		1,400	A	\$ 16.7	2,400			D		
Common Stock		05/21	1/2004				P	•		2,600	A	\$ 16.679	5,000	5,000		D			
Reminder:	Report on a s	separate line	for each	class of secur						Person the	sons whatained i	no responding the responding the responding to t	form are a curre	e not requently valid	ction of inf uired to res I OMB conf	spond unle	ss	C 1474 (9-02)	
		1				outs, cal		arrant		tion	s, conver	tible se	curities)						
Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day	/Year)	3A. Deemed Execution Date, any (Month/Day/Ye		Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		Am Und Sec	Title and ount of derlying urities tr. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owner Form of Deriva Securit Direct or Indi	tive Ownershi (Instr. 4) (D) rect		
						Code	V	(A)	(D)	Dat Exe	e ercisable	Expira Date	tion Titl	Amount or Number of Shares					
Donor	ting O	Whore																	

Reporting Owners

	Relationships								
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
COOPER ROBIN D G 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080			Sr. V.P. Pharmaceutical Scs.						

Dolly Vance (Attorney-in-Fact) Signature of Reporting Person O5/24/2004 Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.